|
|
| Line 1: |
Line 1: |
| | {{Fudan-CHINA}} | | {{Fudan-CHINA}} |
| − | <html>
| |
| − | <head>
| |
| − | <meta charset="utf-8">
| |
| − | <title>Team:Fudan-CHINA -2018.igem.org</title>
| |
| − | <style type="text/css">
| |
| − | body {
| |
| − | background-color:rgba(21,101,126,1.00);!important;
| |
| − | }
| |
| − | .step{font-family:Algerian;
| |
| − | font-size: 1100%;
| |
| − | color: white;
| |
| − | left: 800px;
| |
| − | position: absolute;
| |
| − | top: 230px;
| |
| − | }
| |
| − | .abstract{
| |
| − | font-family:Baskerville, "Palatino Linotype", Palatino, "Century Schoolbook L", "Times New Roman", "serif";
| |
| − | color: white;
| |
| − | font-size: 160%;
| |
| − | position: absolute;
| |
| − | width: 1500px;
| |
| − | left: 200px;
| |
| − | top: 600px;
| |
| − | ;
| |
| − | }
| |
| − | .fullname{
| |
| − | font-family:Cambria, "Hoefler Text", "Liberation Serif", Times, "Times New Roman", "serif";
| |
| − | color: white;
| |
| − | font-size: 200%;
| |
| − | position: absolute;
| |
| − | left:800px;
| |
| − | top:430px;
| |
| − | }
| |
| − | p{text-indent:50px;
| |
| − | }
| |
| − | </style>
| |
| − | </head>
| |
| − |
| |
| − | <body>
| |
| − | <img src="https://static.igem.org/mediawiki/2018/1/1d/T--Fudan-CHINA--step_white.png" width="250" height="250" style="position:absolute; left:500px; top:250px;">
| |
| − | <div class="step">S T E P</div>
| |
| − | <div class="abstract">
| |
| − | <p>Cell therapy has shown great potential in cancer treatment these years, while the existing CAR-T cell therapy can only target on cell surface antigens. </p>
| |
| − | <p>However, there are also many tumour markers free in the blood, also being important targets marking the location of tumour. Here we manage to construct a brand new transducer system, named STEP, to recognise small, soluble tumour markers (e.g. VEGF, AFP, TSGF).</p>
| |
| − | <p>For that purpose, we adapt and optimise a newly developed system to transduce the input (free ligands) into release of a transcription factor and expression of desired drugs. To increase the recognition ability, we use Rosetta to redesign the interface between ligand and receptor in order to enhance the binding affinity. </p>
| |
| − | <p>Our STEP system can be applied for detecting tumour markers in blood and secrete drug in real time to appropriate tissues, providing a new yet practical approach for cell therapy and cancer treatment.</p>
| |
| − | </div>
| |
| − | <div class="fullname">
| |
| − | Synthetic Transducer Engineering Platform
| |
| − | </div>
| |
| − | </body>
| |
| − | </html>
| |
